T-cell receptor and B-cell receptor specific for tetanus toxoid (TT-specific TCR/BCR)

Human adaptive immune receptors recognizing tetanus toxoid comprise the diverse repertoire of T-cell receptors (TCRs) and B-cell receptors (BCRs) specifically evolved to bind epitopes of the tetanus toxoid antigen (Source: PubMed, PMID: 28253129). These receptors play a critical role in the adaptive immune response by facilitating the recognition and subsequent neutralization of the tetanus neurotoxin produced by Clostridium tetani (Source: CDC, Tetanus). BCRs, when activated, lead to the production of protective IgG antibodies, while TCRs (primarily CD4+) provide the cellular signals required for B-cell maturation and memory formation (Source: NIH, Immune System Overview). While these receptors are not targets for pharmacological inhibition, they are the functional endpoints of tetanus vaccination strategies, which utilize the toxoid to stimulate their expansion (Source: WHO, Tetanus Vaccine Position Paper). Tetanus immune globulin (TIG) is a therapeutic product consisting of these specific antibodies harvested from donors, used to provide immediate passive immunity (Source: StatPearls, Tetanus). The quantification of these receptors and their secreted products serves as a key biomarker for assessing individual immunity and vaccine efficacy (Source: IEDB, Tetanus Toxoid Epitopes).

Other names

Anti-tetanus antibodiesTetanus toxoid-specific T-cell receptorsTetanus toxoid-specific B-cell receptorsTT-reactive lymphocytesTetanus-specific adaptive immune receptors

Vaccines provide the tetanus toxoid antigen which binds to these receptors on naive or memory lymphocytes, inducing signal transduction, clonal expansion, and differentiation into effector cells (plasma cells and helper T cells) that neutralize the toxin (Source: Janeway's Immunobiology, 9th Edition).